Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults

BACKGROUND: There is very little known about SARS-CoV-2 vaccine immune responses in New Zealand populations at greatest risk for serious COVID-19 disease. METHODS: This prospective cohort study assessed immunogenicity in BNT162b2 mRNA vaccine recipients in New Zealand without previous COVID-19, with...

Descripción completa

Detalles Bibliográficos
Autores principales: Priddy, Frances H., Williams, Michael, Carson, Simon, Lavender, Brittany, Mathieson, Julia, Frampton, Chris, Moreland, Nicole J., McGregor, Reuben, Williams, Georgia, Brewerton, Maia, Gell, Katie, Ussher, James, Le Gros, Graham
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9273612/
https://www.ncbi.nlm.nih.gov/pubmed/35868948
http://dx.doi.org/10.1016/j.vaccine.2022.07.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9273612/
https://www.ncbi.nlm.nih.gov/pubmed/35868948
http://dx.doi.org/10.1016/j.vaccine.2022.07.009

Ejemplares similares